NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

we have reached the midpoint OS at 166 patients and are waiting for 67 additional events to get to 233. Only the patients falling left of the 166 midpoint will move the OS to the right. All patients falling to the right of the 166 will not move the MOS. Is this correct?

Kinda.

Yes, we've reached 166 OS events and are waiting for 67 more.

But the 166 event patient can keep shifting.

And in the diagram samples I gave, you could see how any patients that fall to the left of the current medium actually pull the medium left - or back -, not to the right - or forward.

In the example, there were 9 OS events and the median was 6 months.

I added 2 OS events at 4 months (to the left of the median), and it pulled the median back from 6 to 5 months.

Then when I instead added the 2 OS events at 8 months, it pulled the median forward to 7 months.

The point being, the longer the current patients live, the further forward the pull the median. And if the current median in the P3 trial is say 24 or 25 months, if those patients who are still living are all past that median (whatever it is), the further to the right they pull the median when they do event.

Here's the link again that shows the three diagrams I made.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=131448683

My only concern is if those long lived patients are higher percentage than 25% of the vaccine group then what if they never event or take longer than 5 years to event?

One would hope that if those patients still living just keep on living and the trial is no closer to reaching 233 events then they were several months ago, eventually, the regulators would step in and halt the trial themselves.

This doesn't happen too often, only in trials where efficacy is very strongly indicated.

But I'd like to think if 25 to 30% of the GBM patients in this trial all reach a certain point in time where it becomes undeniable that DCVax-L is the reason they are still alive, the odds of the regulators stepping in and halting this trial would have to increase.